ATE413190T1 - Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) - Google Patents

Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)

Info

Publication number
ATE413190T1
ATE413190T1 AT00993586T AT00993586T ATE413190T1 AT E413190 T1 ATE413190 T1 AT E413190T1 AT 00993586 T AT00993586 T AT 00993586T AT 00993586 T AT00993586 T AT 00993586T AT E413190 T1 ATE413190 T1 AT E413190T1
Authority
AT
Austria
Prior art keywords
hcv
hepatitis
virus
antibodies
antibodies specific
Prior art date
Application number
AT00993586T
Other languages
English (en)
Inventor
Michael Houghton
Mark Selby
Sergio Abrignani
Jens Heile
Derek O'hagan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE413190T1 publication Critical patent/ATE413190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00993586T 1999-12-01 2000-12-01 Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) ATE413190T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16823499P 1999-12-01 1999-12-01
US18505500P 2000-02-25 2000-02-25

Publications (1)

Publication Number Publication Date
ATE413190T1 true ATE413190T1 (de) 2008-11-15

Family

ID=26863907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00993586T ATE413190T1 (de) 1999-12-01 2000-12-01 Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)

Country Status (12)

Country Link
US (3) US7329408B2 (de)
EP (1) EP1233782B1 (de)
JP (1) JP2004500366A (de)
AT (1) ATE413190T1 (de)
AU (1) AU5442501A (de)
CA (1) CA2393251C (de)
CY (1) CY1108734T1 (de)
DE (1) DE60040755D1 (de)
DK (1) DK1233782T3 (de)
ES (1) ES2319727T3 (de)
PT (1) PT1233782E (de)
WO (1) WO2001047551A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1232267B1 (de) * 1999-10-27 2013-03-20 Novartis Vaccines and Diagnostics, Inc. Aktivierung von hcv-spezifischen t-zellen
ATE413190T1 (de) * 1999-12-01 2008-11-15 Novartis Vaccines & Diagnostic Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
CA2451739A1 (en) * 2001-06-29 2003-01-09 Chiron Corporation Hcv e1e2 vaccine compositions
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
CA2461380C (en) 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
JP2006520746A (ja) * 2002-12-27 2006-09-14 カイロン コーポレイション リン脂質を含む免疫原性組成物
ES2615029T3 (es) * 2003-01-14 2017-06-05 Glaxosmithkline Biologicals Sa Micropartículas que comprenden polinucleótidos adsorbidos en la superficie de micropartículas o atrapados en el interior de las mismas
WO2004071414A2 (en) * 2003-02-05 2004-08-26 Genzyme Corporation Therapeutic anti-hcv (al9) compounds
EP1610757A4 (de) * 2003-04-10 2007-05-30 Transform Pharmaceuticals Inc Profilierung von konformationsvarianten, antikörper-zusammensetzungen und anwendungsverfahren dafür
WO2004096136A2 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
PL1631264T5 (pl) * 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
EP1765386A4 (de) * 2004-05-17 2008-07-30 Novartis Vaccines & Diagnostic Verkürzte ns5-domäne von hepatitis-c-virus sowie diese enthaltende fusionsproteine
DK1765310T3 (en) 2004-05-28 2016-01-11 Oryxe MIXING for transdermal delivery of LAV AND HØJMOLEKYLVÆGTFORBINDELSER
KR101262773B1 (ko) * 2004-08-24 2013-05-10 도레이 카부시키가이샤 자율복제능을 갖는 개변된 인간 ｃ형간염 바이러스 게놈ｒｎａ
EP1870470B1 (de) * 2004-11-18 2011-04-06 National University of Corporation Hiroshima University Verfahren und Kit zur Proteinexpression und Regelung der Expression wiederholter Sequenzen, die durch Genamplifikation und -transformierung gebildet werden
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
AU2008280057A1 (en) 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Antibody having inhibitory activity on infection with hepatitis C virus (HCV), and use thereof
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
CN103533956A (zh) * 2010-11-26 2014-01-22 麦克法兰博尼特医学健康研究公司 组合物及其制备方法
CA2922698C (en) 2013-08-29 2023-01-03 City Of Hope Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
EP3349717A4 (de) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. Ansätze zur verbesserung der hauthydrierung oder -befeuchtung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
ES2012739T5 (es) * 1987-11-18 2001-12-01 Chiron Corp Diagnosticos para nanbv.
US5471330A (en) 1993-07-29 1995-11-28 Honeywell Inc. Polysilicon pixel electrode
DE69534296T2 (de) 1994-07-29 2006-04-27 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Sezernierter E1/E2-Komplex des Hepatitis C-Virus, des aus C-terminal verkürzten Polypeptiden E1 und E2 erhalten ist
PT773957E (pt) 1994-07-29 2005-11-30 Chiron Corp Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
EP0862419B2 (de) * 1995-11-09 2010-11-17 Microbiological Research Authority Mikroverkapselte dna zur impfung und gentherapie
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
ES2328536T3 (es) 1997-05-06 2009-11-13 Novartis Vaccines And Diagnostics, Inc. Produccion intracelular de polipeptido e2 truncado de la hepatitis c.
WO1999004010A1 (en) * 1997-07-18 1999-01-28 Connaught Laboratories Limited Nucleic acid vaccines encoding g protein of respiratory syncytial virus
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
EP1232267B1 (de) 1999-10-27 2013-03-20 Novartis Vaccines and Diagnostics, Inc. Aktivierung von hcv-spezifischen t-zellen
ATE413190T1 (de) * 1999-12-01 2008-11-15 Novartis Vaccines & Diagnostic Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)

Also Published As

Publication number Publication date
DE60040755D1 (de) 2008-12-18
EP1233782A2 (de) 2002-08-28
DK1233782T3 (da) 2009-02-09
US7329408B2 (en) 2008-02-12
EP1233782B1 (de) 2008-11-05
US20110159039A1 (en) 2011-06-30
US20020002272A1 (en) 2002-01-03
WO2001047551A3 (en) 2002-03-14
PT1233782E (pt) 2009-02-13
CA2393251C (en) 2012-01-31
WO2001047551A2 (en) 2001-07-05
US20080095800A1 (en) 2008-04-24
ES2319727T3 (es) 2009-05-12
CA2393251A1 (en) 2001-07-05
CY1108734T1 (el) 2014-04-09
AU5442501A (en) 2001-07-09
JP2004500366A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
CY1108734T1 (el) Αναπτυξη αντισωματων ειδικων για hcv
WO2002061576A3 (en) System, method and article of manufacture for interface constructs in a programming language capable of programming hardware architectures
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
MXPA03006702A (es) Metodo para la identificacion, aislamiento y produccion de antigenos para un patogeno especifico.
IL152825A0 (en) Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
NO20051715L (no) HCV assay
FI935217A0 (fi) Basisk dissocieringsanalys
DE69730152D1 (de) Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
DK1230932T3 (da) Anvendelse af antistoffer til vaccinering mod cancer
AU5686890A (en) Mouse monoglonal antibodies for post-exposure treatment of rabies
NO883603D0 (no) Humane monoklonale antistoffer og profylaktiske og terapeutiske midler mot infektioese sykdommer inneholdende disse som effektiv bestanddel.
EP0339668A3 (de) Hepatitis-A-Virus aufgebautes Antigen
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
DK0556320T3 (da) Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf
ATE135013T1 (de) Verfahren zur erhöhung der rate der modifikation metastabiler bindungen
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DE68918440D1 (de) Verfahren zur transformation von menschlichen b-lymphocyten.
DK0599913T3 (da) Monoklonale antistoffer mod formodet hepatitis C-virus NS5-proteiner og anvendelsesmetoder af samme
EP1394548A3 (de) Methode zur serologischen Typisierung mittels typspezifischer Antigene
WO2001093804A3 (en) Hepatitis c virus conjugates
GB2229725B (en) A method of enhancing neutralising antibody activity in human or animal sera or in other body secreations

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1233782

Country of ref document: EP